Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4+ T lymphocytes - 04/02/21
![](/templates/common/images/mail.png)
This study was funded in part by a grant from the German Cystic Fibrosis Association Mukoviszidose e.V. (grant no. 1705). M.O. is a postdoctoral researcher funded by the Biotechnology and Biological Sciences Research Council (BBSRC, grant no. BB/R008108/1). M.A.M. has been supported by grants from the German Federal Ministry of Education and Research (grant no. 82DZL004A1) and the Einstein Foundation Berlin (grant no. EP-2017-393). |
|
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflict of interest. |
Vol 147 - N° 2
P. 753-756 - Febbraio 2021 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?